ZA201706923B - T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car) - Google Patents

T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car)

Info

Publication number
ZA201706923B
ZA201706923B ZA2017/06923A ZA201706923A ZA201706923B ZA 201706923 B ZA201706923 B ZA 201706923B ZA 2017/06923 A ZA2017/06923 A ZA 2017/06923A ZA 201706923 A ZA201706923 A ZA 201706923A ZA 201706923 B ZA201706923 B ZA 201706923B
Authority
ZA
South Africa
Prior art keywords
cell
receptor
tcr
expresses
delta
Prior art date
Application number
ZA2017/06923A
Other languages
English (en)
Inventor
Anderson John
Fisher Jonathan
PULÉ Martin
Gustafsson Kenth
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of ZA201706923B publication Critical patent/ZA201706923B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2017/06923A 2015-04-30 2017-10-12 T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car) ZA201706923B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1507368.7A GB201507368D0 (en) 2015-04-30 2015-04-30 Cell
PCT/GB2016/051235 WO2016174461A1 (en) 2015-04-30 2016-04-29 T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car)

Publications (1)

Publication Number Publication Date
ZA201706923B true ZA201706923B (en) 2022-02-23

Family

ID=53488907

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/06923A ZA201706923B (en) 2015-04-30 2017-10-12 T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car)

Country Status (16)

Country Link
US (2) US20180125890A1 (enExample)
EP (1) EP3288567B1 (enExample)
JP (1) JP6986449B2 (enExample)
KR (1) KR20180020140A (enExample)
CN (1) CN107771215A (enExample)
AU (1) AU2016255611B2 (enExample)
BR (1) BR112017023409A2 (enExample)
CA (1) CA2982532C (enExample)
EA (1) EA201792042A1 (enExample)
ES (1) ES3018558T3 (enExample)
GB (1) GB201507368D0 (enExample)
HK (1) HK1252235A1 (enExample)
IL (1) IL255186B (enExample)
SG (1) SG11201708402UA (enExample)
WO (1) WO2016174461A1 (enExample)
ZA (1) ZA201706923B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
KR102211120B1 (ko) 2014-05-15 2021-02-03 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
CN112695050B (zh) * 2017-03-24 2025-08-08 莱蒂恩技术公司 用于用抗cd33免疫疗法治疗癌症的组合物和方法
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
US20210130775A1 (en) * 2017-08-02 2021-05-06 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
CA3076817A1 (en) * 2017-09-27 2019-04-04 Ohio State Innovation Foundation Tissue factor-targeting car-nk and car-t cell therapy
GB201715918D0 (en) 2017-09-29 2017-11-15 Tc Biopharm Ltd Modified CAR-T
GB201720949D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Cell
CN111801348A (zh) 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
GB201804701D0 (en) * 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2019192526A1 (zh) * 2018-04-04 2019-10-10 达仁生物科技有限公司 嵌合抗原受体和其治疗癌症的方法
CN112004924A (zh) * 2018-04-18 2020-11-27 Ucl商务有限公司 增强treg细胞抑制特性的方法
CN108588023B (zh) * 2018-05-09 2020-02-14 河北森朗生物科技有限公司 一种生产嵌合抗原受体修饰的γδT细胞的方法
CN110577932A (zh) * 2018-06-07 2019-12-17 亘喜生物科技（上海）有限公司 一种脐带血来源的嵌合抗原受体t细胞
CN119529091A (zh) * 2018-06-19 2025-02-28 南京传奇生物科技有限公司 工程化的细胞及其用途
TWI809130B (zh) * 2018-06-22 2023-07-21 美商凱特製藥公司 嵌合跨膜蛋白及其用途
EP3831936A4 (en) 2018-07-31 2022-04-13 Thyas Co. Ltd. METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS
US12569507B2 (en) 2018-08-07 2026-03-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T-cells for the treatment of bone metastatic cancer
US12156888B2 (en) 2018-08-07 2024-12-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T-cells for the treatment of bone metastatic cancer
EP4455166A3 (en) * 2018-08-10 2025-01-15 Kyoto University Method for producing cd3-positive cell
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
BR112021005184A8 (pt) * 2018-09-19 2022-08-16 Lava Therapeutics B V Imunoglobulina cd1d de dupla ação
CN109234236A (zh) * 2018-09-29 2019-01-18 吉林大学第医院 一种嵌合抗原受体γδT细胞的制备方法
JP7687952B2 (ja) * 2018-10-01 2025-06-03 アディセット セラピューティクス， インク． 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法
MX2021003744A (es) * 2018-10-01 2021-06-23 Adicet Bio Inc Composiciones y métodos relacionados con linfocitos t gamma delta modificados y no modificados para el tratamiento de tumores sólidos.
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
KR20210121136A (ko) * 2019-01-29 2021-10-07 상하이 지아오통 유니버시티 키메라 항원 수용체 및 그 용용
WO2020172555A1 (en) * 2019-02-21 2020-08-27 Regents Of The University Of Minnesota Genetically modified gamma delta t cells and methods of making and using
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
US20220162301A1 (en) * 2019-04-12 2022-05-26 PhanesTherapeutics, Inc. Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof
AU2020261886A1 (en) * 2019-04-22 2021-11-18 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
WO2020251046A1 (ja) 2019-06-14 2020-12-17 サイアス株式会社 医薬組成物
AU2020296197A1 (en) * 2019-06-21 2022-01-20 Shattuck Labs, Inc. Chimeric protein expressing T-cells
GB201909283D0 (en) * 2019-06-27 2019-08-14 Cancer Research Tech Ltd Fusion proteins with enzyme activity
CN110981972B (zh) * 2019-12-25 2022-09-30 华夏源（上海）细胞基因工程股份有限公司 一种分泌双特异性抗体的嵌合抗原受体及其表达载体和应用
WO2021176373A1 (en) * 2020-03-03 2021-09-10 Janssen Biotech, Inc. ꝩδ T CELLS AND USES THEREOF
JP7699154B2 (ja) 2020-05-22 2025-06-26 重▲慶▼精准生物技▲術▼有限公司 腫瘍微小環境を逆転させる融合タンパク質及びその使用
CA3189671A1 (en) 2020-07-17 2022-01-20 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
US11945876B2 (en) 2021-06-16 2024-04-02 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
WO2023288278A1 (en) 2021-07-16 2023-01-19 Instil Bio (Uk) Limited Chimeric molecules providing targeted costimulation for adoptive cell therapy
CN113528455A (zh) * 2021-07-19 2021-10-22 广州百暨基因科技有限公司 表达嵌合抗原受体的γδT细胞
EP4413029A4 (en) * 2021-10-06 2025-08-20 Dana Farber Cancer Inst Inc MODIFIED CYTOKINE RECEPTORS FOR TREATABLE ADOPTIVE CELL THERAPY

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144339A0 (en) 1999-01-28 2002-05-23 Palmetto Health Alliance A cell line containing gamma delta lymphocytes and pharmaceutical compositions containing the same
JP4982645B2 (ja) 2000-04-03 2012-07-25 セラピュア バイオファーマ インコーポレーテッド ＴｃＲガンマデルタＴ細胞の産生
JP4361727B2 (ja) 2000-09-11 2009-11-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド チロシンキナーゼインヒビターとしてのキノリノン誘導体
JPWO2006006720A1 (ja) 2004-07-13 2008-05-01 株式会社メディネット γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
DK1778836T3 (da) 2004-08-19 2010-11-22 Univ Cardiff Fremstilling af antigenpræsenterende humane gammadelta-T-celler og anvendelse ved immunterapi
WO2008152822A1 (ja) 2007-06-15 2008-12-18 Medinet Co., Ltd. 医薬
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9833476B2 (en) * 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
EP3594245A1 (en) * 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
AU2014214850C1 (en) 2013-02-06 2018-12-06 Celgene Corporation Modified T lymphocytes having improved specificity
LT2958943T (lt) * 2013-02-20 2020-01-27 The Trustees Of The University Of Pennsylvania Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
TWI654206B (zh) * 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
EP3974520A1 (en) * 2013-05-14 2022-03-30 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3027204B1 (en) * 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
CN105848484A (zh) 2013-10-25 2016-08-10 得克萨斯州大学系统董事会 用于免疫治疗的多克隆γδ T细胞
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
MX377283B (es) * 2013-11-21 2025-03-07 Ucl Business Ltd Célula t o nk que coexpresa un receptor antigénico quimérico (car).
CA3190002A1 (en) * 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
GB201403972D0 (en) * 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
US20170158749A1 (en) * 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
BR112017000464A2 (pt) 2014-07-09 2017-11-07 Tc Biopharm Ltd células gama delta t e uso das mesmas
IL252131B2 (en) 2014-11-17 2023-04-01 Adicet Bio Inc Transgenic gamma delta T cells
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
CN105158466B (zh) 2015-05-05 2017-12-22 中国科学院广州生物医药与健康研究院 一种检测抗cd19的嵌合抗原受体t细胞对白血病细胞抑制作用的方法

Also Published As

Publication number Publication date
BR112017023409A2 (en) 2018-07-24
JP6986449B2 (ja) 2021-12-22
WO2016174461A1 (en) 2016-11-03
CA2982532C (en) 2023-10-03
EP3288567A1 (en) 2018-03-07
EP3288567B1 (en) 2025-03-19
US12331316B2 (en) 2025-06-17
CN107771215A (zh) 2018-03-06
JP2018514204A (ja) 2018-06-07
AU2016255611B2 (en) 2021-08-05
CA2982532A1 (en) 2016-11-03
HK1252235A1 (zh) 2019-05-24
AU2016255611A1 (en) 2017-11-02
IL255186A0 (en) 2017-12-31
KR20180020140A (ko) 2018-02-27
IL255186B (en) 2022-02-01
US20180125890A1 (en) 2018-05-10
SG11201708402UA (en) 2017-11-29
GB201507368D0 (en) 2015-06-17
ES3018558T3 (es) 2025-05-16
US20220211756A1 (en) 2022-07-07
EA201792042A1 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
IL255186B (en) T cell that expresses T cell gamma delta receptor (tcr) and chimeric antigen receptor (car)
IL292508B1 (en) A cell that simultaneously expresses a chimeric antigen receptor (car) of 19cd and 22cd
IL261525A (en) Cells expressing multiple chimeric receptor-antigen molecules (car) and their use
IL254254B (en) chimeric antigen receptor
DK3265490T3 (en) Chimeric antigen receptor (car) comprising a cd19-binding domain
SG10201913247XA (en) Antibody/t-cell receptor chimeric constructs and uses thereof
EP3286225A4 (en) Cd5 chimeric antigen receptor for adoptive t cell therapy
GB201607968D0 (en) Chimeric antigen receptor
IL256058B (en) Lym-1 and lym-2 targeted car cell immunotherapy
SG11201606790XA (en) Chimeric antigen receptor
GB201610512D0 (en) Chimeric antigen receptor
IL257295B (en) Chimeric antigen receptors, and T cells in which expression of a chimeric antigen receptor is measured
EP3186284A4 (en) Conditionally active chimeric antigen receptors for modified t-cells
ZA201906321B (en) Chimeric antigen receptor
IL266950B1 (en) γδ t cells expressing a chimeric antigen receptor for use in immunotherapy
PL3529267T3 (pl) Receptor komórek t
GB201709508D0 (en) Chimeric antigen receptor
GB201810451D0 (en) Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
GB201519900D0 (en) Chimeric antigen receptor
GB201721421D0 (en) Chimeric antigen receptor
HK40022368A (en) A cell comprising a chimeric antigen receptor (car)
GB201721831D0 (en) T cell antigen receptor chimera
AU2016902764A0 (en) Chimeric antigen receptor modified T cells
GB201612844D0 (en) Chimeric antigen receptor
GB201612533D0 (en) Chimeric antigen receptor